Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 507

Sort by

Sort Order Select

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Blood (2025) 146 (20): 2443–2456.

https://doi.org/10.1182/blood.2024027822

Published: 2025

Includes: Supplemental data

Journal Articles

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Blood (2025) 146 (19): 2293–2305.

https://doi.org/10.1182/blood.2025028730

Published: 2025

Includes: Supplemental data

Journal Articles

Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.

Arjan Van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Janine Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Alex Karlsson-Parra, Tariq Mughal, Bjorn Gjertsen

Blood (2025) 146 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2025-1647

Published: 2025

Journal Articles

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Marie Sebert, Valeria Santini, Uwe Platzbecker, David Valcarcel, Uma Borate, Weishi Yuan, Stephanie Kapsalis, Lorene Simonot, Marissa Panzica, Prapti Patel, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 8254.

https://doi.org/10.1182/blood-2025-8254

Published: 2025

Journal Articles

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

Blood (2025) 146 (Supplement 1): 4968.

https://doi.org/10.1182/blood-2025-4968

Published: 2025

Journal Articles

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Blood (2025) 146 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2025-2074

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

Sarcopenia and body composition predict survival and reveal immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma

Blood (2025) 146 (Supplement 1): 7676.

https://doi.org/10.1182/blood-2025-7676

Published: 2025

Journal Articles

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma

Nora Grieb, Thomas Wiemers, Patrick Born, David Fandrei, Luise Fischer, Maximilian Ferle, Song-Yau Wang, Madlen Jentzsch, Carmen Herling, Klaus Metzeler, Marco Herling, Simone Heyn, Uwe Platzbecker, Vladan Vucinic, Thomas Neumuth, Georg-Nikolaus Franke, Maximilian Merz

Blood (2025) 146 (Supplement 1): 5853.

https://doi.org/10.1182/blood-2025-5853

Published: 2025

Journal Articles

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Klaus Metzeler, Jens Przybilla, Anne Weigert, Mathias Hänel, Thomas Illmer, Julia Pross, Alexander Höllein, Martin Schmidt-Hieber, Ullrich Graeven, Tim Sauer, Stefan Neuburger, Katharina S. Götze, Dominic Brauer, Madlen Jentzsch, Christoph Röllig, Dirk Hasenclever, Uwe Platzbecker

Blood (2025) 146 (Supplement 1): 46.

https://doi.org/10.1182/blood-2025-46

Published: 2025

Journal Articles

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Guillermo Garcia-Manero, Manuel Ugidos, Maroof Hasan, Matthew Stokes, Matteo Della Porta, Amer Zeidan, Valeria Santini, Uwe Platzbecker, Rami Komrokji, Dimana Miteva, Veronika Pozharskaya, Anita Gandhi, Daniel Lopes de Menezes, Rajasekhar Suragani

Blood (2025) 146 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2025-5613

Published: 2025

Journal Articles

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

Uwe Platzbecker, Elena Crisa, Sophie Salazar, Thomas Cluzeau, Antonella Poloni, Raquel De Paz Arias, Thibault Comont, Sebastian Grosicki, Aristoteles Giagounidis, Matteo Della Porta, Pellegrino Musto, Mar Tormo, Dominic Brauer, Ana Alfonso-Pierola, Stefania Paolini, Sophie Park, Annelies Weyn, Lionel Ades, Valeria Santini

Blood (2025) 146 (Supplement 1): 5649.

https://doi.org/10.1182/blood-2025-5649

Published: 2025

Journal Articles

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

Lionel Ades, Steven Lane, Alice Garnier, Thomas Cluzeau, Odile Rauzy, Katharina S. Götze, Aristoteles Giagounidis, Deepak Singhal, Dominic Brauer, Carolyn Grove, Katharina Mohr, Fatiha Chermat, Joanna Nkyekyer, Uwe Platzbecker

Blood (2025) 146 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2025-5155

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Sarcopenia and body composition predict survival and reveal immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma

Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only